True effect of monoclonal antibody for COVID-19 in kidney transplant recipients
- PMID: 34897967
- PMCID: PMC9849506
- DOI: 10.1111/ajt.16922
True effect of monoclonal antibody for COVID-19 in kidney transplant recipients
Keywords: clinical research/practice; infection and infectious agents - viral; infection and infectious agents - viral: SARS-CoV-2/COVID-19; infectious disease; kidney transplantation/nephrology.
Comment on
-
Use of anti-spike monoclonal antibodies in kidney transplant recipients with COVID-19: Efficacy, ethnic and racial disparities.Am J Transplant. 2022 Feb;22(2):640-645. doi: 10.1111/ajt.16843. Epub 2021 Sep 30. Am J Transplant. 2022. PMID: 34591350 Free PMC article.
References
-
- Food and Drug Administration Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19FDA authorizes REGEN-COV monoclonal antibody therapy for post-exposure prophylaxis (prevention) for COVID-19. FDA News Release. https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-re.... Updated November 21, 2020. Accessed October 10, 2020.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
